{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:54Z","timestamp":1786988994213,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The John and Carol Walter Family Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euf.2025.05.022","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T15:58:23Z","timestamp":1750953503000},"page":"951-958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"Ian M.","family":"McElree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Y.","family":"Hougen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.05.022_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0015","unstructured":"Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment. 2024."},{"key":"10.1016\/j.euf.2025.05.022_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0030","article-title":"IL-15 superagonist NAI in BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euf.2025.05.022_b0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2025.05.022_b0045","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000002848","article-title":"Sequential intravesical valrubicin and docetaxel for the salvage treatment of non-muscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0055","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.3390\/cancers16244126","article-title":"Sequential endoluminal doxorubicin and gemcitabine alternating weekly with sequential mitomycin and docetaxel for recurrent non-muscle invasive urothelial carcinoma","volume":"16","author":"McElree","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.05.022_b0060","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/cancers16142561","article-title":"Sequential endoluminal gemcitabine and cabazitaxel with intravenous pembrolizumab as a bladder-preserving strategy for docetaxel-unresponsive non-muscle invasive urothelial carcinoma following transurethral resection of bladder tumor","volume":"16","author":"McElree","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.05.022_b0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bju.16208","article-title":"Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer","volume":"133","author":"McElree","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.05.022_b0070","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.euf.2025.05.022_b0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1200\/JCO.2021.39.6_suppl.451","article-title":"Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Gu\u00e9rin: extended follow-up of KEYNOTE-057 cohort A","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0080","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0085","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2024.42.16_suppl.4601","article-title":"Final results of CORE-001: a phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0090","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.euf.2019.09.006","article-title":"Overview of Taris GemRIS, a novel drug delivery system for bladder cancer","volume":"6","author":"Grimberg","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.05.022_b0095","doi-asserted-by":"crossref","first-page":"S1272","DOI":"10.1016\/j.annonc.2024.08.2329","article-title":"LBA85 TAR-200 +\/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Gu\u00e9rin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): updated results from SunRISe-1 (SR-1)","volume":"35","author":"van der Heijden","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0105","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.urolonc.2024.01.144","article-title":"Oncologic outcomes of bladder-sparing management for high-grade non-invasive urothelial carcinoma of the prostatic urethra","volume":"42","author":"Martin","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0302-2838(02)00581-X","article-title":"A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire","volume":"43","author":"Chahal","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2007.10.069","article-title":"Prognostic impact of comorbidity in patients with bladder cancer","volume":"53","author":"Megwalu","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.022_b0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.euf.2025.05.022_b0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bju.16509","article-title":"Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"135","author":"Taylor","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.05.022_b0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2025.05.022_b0135","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692500152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692500152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:13:10Z","timestamp":1765404790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692500152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S240545692500152X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.022","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}